| Trastuzumab deruxtecan in previously treated HER2-positive breast cancer S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ... New England Journal of Medicine 382 (7), 610-621, 2020 | 1820 | 2020 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1810 | 2022 |
| MONARCH 3: abemaciclib as initial therapy for advanced breast cancer MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... Journal of Clinical Oncology 35 (32), 3638-3646, 2017 | 1712 | 2017 |
| MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy GW Sledge Jr, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... Journal of clinical oncology 35 (25), 2875-2884, 2017 | 1691 | 2017 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1631 | 2012 |
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic … DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ... Journal of clinical oncology 28 (20), 3239-3247, 2010 | 1103 | 2010 |
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ... The lancet oncology 19 (7), 904-915, 2018 | 1051 | 2018 |
| Overall survival with ribociclib plus endocrine therapy in breast cancer SA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ... New England journal of medicine 381 (4), 307-316, 2019 | 1032 | 2019 |
| The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a … GW Sledge, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... JAMA oncology 6 (1), 116-124, 2020 | 949 | 2020 |
| Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple … EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Koehler, ... The Lancet 396 (10257), 1090-1100, 2020 | 940 | 2020 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 781 | 2020 |
| Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE) SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ... Journal of Clinical Oncology 38 (34), 3987-3998, 2020 | 778 | 2020 |
| Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP) HS Moon, K Kwon, SI Kim, H Han, J Sohn, S Lee, HI Jung Lab on a Chip 11 (6), 1118-1125, 2011 | 530 | 2011 |
| Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind … SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ... The Lancet Oncology 18 (10), 1360-1372, 2017 | 529 | 2017 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246-3256, 2022 | 462 | 2022 |
| Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 … P Schmid, R Salgado, YH Park, E Muñoz-Couselo, SB Kim, J Sohn, SA Im, ... Annals of Oncology 31 (5), 569-581, 2020 | 364 | 2020 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 356 | 2021 |
| Capivasertib in hormone receptor–positive advanced breast cancer NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ... New England Journal of Medicine 388 (22), 2058-2070, 2023 | 348 | 2023 |
| Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review K Pandey, HJ An, SK Kim, SA Lee, S Kim, SM Lim, GM Kim, J Sohn, ... International journal of cancer 145 (5), 1179-1188, 2019 | 317 | 2019 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 278 | 2022 |
